Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer
Endocrine-Related Cancer · 2025
DOI: 10.1530/erc-24-0208 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Samuel P G Rollin und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Receptors, Androgen, Prostatic Neoplasms, Androgens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 220 Literaturangaben.
Abstract (Originalsprache)
Inhibiting the activity of the androgen receptor (AR) is the cornerstone treatment for advanced prostate cancer. AR-targeted therapies are highly effective in slowing disease progression but are not curative. Failure of these therapies results in a disease state termed castration-resistant prostate cancer, which is associated with significant patient morbidity and mortality. In most cases, resistance to AR-targeted therapies arises due to alterations that reactivate the AR signalling axis. Interestingly, it has long been recognised that potent activation of AR with supraphysiological levels of androgens can suppress prostate cancer growth in both preclinical models and patients. This intriguing paradox, where both inhibition and activation of AR have anti-cancer effects, is now being harnessed clinically in the form of bipolar androgen therapy (BAT). This review describes mechanisms underlying the tumour-suppressive functions of AR in the context of potent androgenic stimulation and discusses how our maturing understanding of these processes is influencing the clinical deployment of BAT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Luke A Selth
Zitieren
APA
Rollin, S. P. G., Lawrence, M. G., Joshua, A. M., & Selth, L. A. (2025). Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0208
Vancouver
Rollin SPG, Lawrence MG, Joshua AM, Selth LA. Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0208
BibTeX
@article{Rollin2025,
author = {Rollin, Samuel P G and Lawrence, Mitchell G and Joshua, Anthony M and Selth, Luke A},
title = {Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer},
journal = {Endocrine-Related Cancer},
year = {2025},
doi = {10.1530/erc-24-0208}
}
EUVIMED